Stifel downgraded Reata Pharmaceuticals (RETA) to Hold from Buy with a price target of $172.50, up from $110. Biogen (BIIB) agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3B. Skyclarys fits “easily into (Biogen’s) rare disease footprint,” says the firm, which adds that it thinks “this was an excellent price for” Reata.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RETA:
- Biogen Snaps Up Reata Pharma In $7.3B Deal
- Biogen to acquire Reata Pharmaceuticals for $172.50 per share in cash
- Biotech Alert: Searches spiking for these stocks today
- 3 Best Stocks to Buy Now, 7/25/2023, According to Top Analysts
- Reata Pharmaceuticals price target raised to $145 from $110 at Cantor Fitzgerald
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue